Exhibit 99.1

      MEDICOR LTD. ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE BREAST IMPLANT
             MANUFACTURER BIOSIL LIMITED AND SUPPLIER NAGOR LIMITED

    LAS VEGAS, Sept. 13 /PRNewswire-FirstCall/ -- Las Vegas-based MediCor Ltd.
(OTC Bulletin Board: MDCR) announced today that it has signed a definitive
agreement to acquire British breast implant manufacturer Biosil Limited and
supplier Nagor Limited for cash and stock.

    Biosil and Nagor are privately owned companies located in the United
Kingdom, with sales of medical devices worldwide. Biosil and MediCor's
subsidiary, MediCor Aesthetics, are currently party to a supply agreement for
saline-filled breast implants manufactured by Biosil and imported into the
United States, subject to United States Food and Drug Administration approval to
market those products. The closing of the acquisition is subject to customary
conditions and is expected to occur by the end of the year.

    Nagor currently supplies the breast implant products manufactured by Biosil
in approximately 60 countries throughout Europe, Asia, South America and Africa.
Biosil employs approximately 90 people in its two ISO-certified manufacturing
facilities, both of which have additional production capacity, thus enhancing
MediCor's ability to meet increased product demand and support new product
introductions. With the acquisition of Biosil and Nagor, MediCor believes it now
controls approximately 30% of the worldwide breast implant market, excluding the
United States.

    Biosil develops and manufactures, and Nagor markets, a full range of
silicone implants for the aesthetic, plastic and reconstructive surgery markets,
including silicone gel and saline-filled breast implants, with both round and
anatomical shapes and smooth or unique micro-textured surfaces. Biosil also
manufactures a range of other silicone devices, including tissue expanders,
testicular implants, gluteal implants, calf implants, facial implants and a
range of scar management products. Biosil has also developed innovative products
within the anesthesia and colorectoral disciplines.

    According to Theodore R. Maloney, MediCor's Chief Executive Officer, "The
acquisition of these companies, combined with our existing Eurosilicone breast
implant product line, will further strengthen the position of MediCor as the
third leading manufacturer and distributor of breast implants worldwide, with
Inamed Corporation and Mentor Corporation in first and second position
worldwide. This acquisition continues the execution of our long-term strategies
of assembling the most experienced management team and acquiring and expanding
businesses in the global aesthetic, plastic and reconstructive and dermatology
markets, continuing the process started with our acquisition of Eurosilicone in
France in July 2004. We are proud to unite in this effort with the Biosil and
Nagor teams, who, like the MediCor companies, are excited to develop the world's
highest quality and leading edge product offerings and service for the growing
aesthetic, plastic and reconstructive surgery markets."

    MediCor intends to retain the current Biosil and Nagor employee base and
expand operations, which are located in Scotland, England and the Isle of
Man. Additionally, John Alsop has agreed to continue in the positions of
President and Managing Director of Nagor following the acquisition, helping
maintain consistency of quality, service and innovation. Maloney also added
that, "MediCor values the breadth and strength of the two companies' existing
third-party distributors worldwide, and we look forward to building upon those
relationships." John Alsop added, "This acquisition brings together a wealth of
experience within the plastic surgery field and will allow the MediCor family of
companies to uniquely dovetail our core competencies, thereby realizing
significant efficiencies and allowing the MediCor companies to leverage these
competencies into market leadership positions. We are excited to be part of the
continuing and ambitious growth of the MediCor group, which will bring exciting
new opportunities to our customers, distributors and employees."



    MediCor Chairman, Donald K. McGhan, further stated, "Nagor and Biosil
founders Gordon and Nancy Evans and I have had strong business associations for
the past 40 years, dating back to the development of the first silicone gel
breast implant, at which time Gordon and Nancy led the international marketing
and sales of Dow Corning's Medical Products Division. In the mid-1970s, Gordon
and Nancy accepted the opportunity to work at McGhan Medical International
located in Brussels, Belgium. In 1979, they left McGhan Medical, then a wholly
owned subsidiary of 3-M Company, to start Nagor and subsequently Biosil. We
could not be more pleased and honored to have this opportunity to be reunited
with Gordon and Nancy and benefit from the knowledge, experience and integrity
that both, along with John Alsop, have instilled in Nagor and Biosil."

    As part of the acquisition, MediCor has agreed to grant certain rights to
the selling shareholders to have the MediCor stock to be issued to them in the
transaction registered with the Securities and Exchange Commission. As a result,
MediCor anticipates that it will further amend and not seek effectiveness of its
current SB-2 registration statement on file with the SEC until some time after
the closing of the acquisition of Biosil and Nagor.

    MediCor was founded by Chairman of the Board Donald K. McGhan, the pioneer
of the modern day breast implant industry. The Company acquires, develops,
manufactures and markets products for medical specialties in aesthetic, plastic
and reconstructive surgery and dermatology markets. Products include surgically
implantable prostheses for aesthetic, plastic and reconstructive surgery and
scar management products. Its products are sold worldwide to hospitals, surgery
centers and physicians through various distributors and direct sales personnel.
MediCor's strategy is to be the leading integrator of selected international
medical device markets, technologies and corporations. To achieve this strategy,
MediCor intends to build upon and expand its business lines, primarily in the
aesthetic, plastic and reconstructive surgery and dermatology markets. MediCor
intends to accomplish this growth through the expansion of existing product
lines and offerings and through the acquisition of companies and other assets,
including intellectual property rights or distribution rights.

    This release may contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements are based
upon the current beliefs and expectations of MediCor's management and are
subject to significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements.



    The following factors, among others, could cause actual results to differ
from those set forth in the forward-looking statements: the ability to obtain
requisite financing, the risk of instability in the capital markets in the U.S.
and internationally, the ability to obtain governmental approvals of the
transactions; the ability to satisfy any agreed closing conditions; the risk
that the businesses will not be integrated successfully; the risk that cost
savings from acquisition transactions may not be realized or may take longer to
realize than expected; disruption from transactions making it more difficult to
maintain relationships with customers, employees or suppliers; increased
competition and its effect on pricing, spending, third-party relationships and
revenues; the outcome of certain political and legal proceedings; the risk of
new and changing regulations in the U.S. and internationally. Additional factors
that could cause MediCor's results to differ materially from those described in
the forward-looking statements can be found in the Annual Report on Form 10-KSB
for the year ended June 30, 2004, and subsequent Quarterly Reports on Form
10-QSB of MediCor filed with the Securities and Exchange Commission and
available at the Securities and Exchange Commission's Internet site
(http://www.sec.gov).

SOURCE  MediCor Ltd.
    -0-                             09/13/2005
    /CONTACT:  Marc S. Sperberg, +1-702-932-4560 ext. 308, for MediCor Ltd. /
    /Web site:  http://medicorltd.com /
    (MDCR)